Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide Plus Apatinib in Newly Diagnosed High-grade Glioma
NCT03741244Phase 2Unknown
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- May 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in glioma, sponsored by The Second Hospital of Hebei Medical University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03741244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03741244.